Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Clopidogrel: how good is it and how does it work?

Richard A Santa-Cruz1, Steven R Steinhubl

  • 1Division of Cardiology, University of North Carolina, 130 Mason Farm Road, Chapel Hill, NC 27599-7075, USA.

Current Cardiology Reports
|June 9, 2004
PubMed
Summary

Aspirin therapy alone is insufficient for preventing thrombotic events in many patients with atherothrombotic disease. Combining clopidogrel with aspirin offers enhanced protection by targeting broader aspects of platelet activation.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Post-vaccine inflammation tracking: validation of a novel individualized digital inflammatory biomarker relative to serum biomarkers.

NPJ digital medicine·2026
Same author

Direct-to-Participant Enrollment in a Virtual Trial: Lessons Learned From the Heartline Study.

JACC. Advances·2026
Same author

Deep Learning-Enabled Diabetic Retinopathy Screening: A Techno-Clinical Revolution or Just More Artificial Intelligence Hype?

Diabetes care·2026
Same author

Diverging trajectories of trust in healthcare and on-line information seeking: what's next with LLMs.

NPJ digital medicine·2026
Same author

Associations Between Online Search Trends and Outpatient Visits for Common Medical Symptoms in the United States from 2004 to 2019: Time Series Ecological Study.

JMIR formative research·2025
Same author

Recent-onset atrial fibrillation: challenges and opportunities.

European heart journal·2025

Area of Science:

  • Cardiology
  • Pharmacology
  • Vascular Biology

Background:

  • Atherothrombotic disease complications pose significant risks despite current treatments.
  • Long-term antiplatelet therapy has historically relied on aspirin, showing limitations in preventing recurrent events.
  • Approximately 75% of high-risk patients experience thrombotic events even with chronic aspirin use.

Purpose of the Study:

  • To evaluate the efficacy of newer antiplatelet agents in managing atherothrombotic disease.
  • To investigate the benefits of combining clopidogrel with aspirin compared to aspirin monotherapy.
  • To explore the mechanistic basis for improved outcomes with combination antiplatelet therapy.

Main Methods:

  • Review of clinical trial data comparing aspirin alone versus aspirin plus clopidogrel.

Related Experiment Videos

  • Analysis of outcomes in patients with atherothrombotic disease receiving different antiplatelet regimens.
  • Investigation into the pathways of platelet activation inhibited by clopidogrel.

    • Main Results:

    • Combination therapy with clopidogrel and aspirin demonstrates superior efficacy over aspirin alone.
    • Clinical trials confirm significant benefits of dual antiplatelet therapy in reducing thrombotic events.
    • Ongoing large-scale trials are further investigating the impact of these therapies.

    Conclusions:

    • Clopidogrel represents a valuable addition to antiplatelet treatment strategies for atherothrombotic disease.
    • The benefit of combination therapy extends beyond simple platelet aggregation inhibition.
    • Enhanced protection is achieved by targeting vascular inflammation, endothelial dysfunction, and angiogenesis.